Reference
·Primary source
Genome Thailand WGS cohort buildout (2024-2027)
50K WGS, 200K array (2027 target)
The Genome Thailand programme targets 50,000 whole-genome sequences plus 200,000 array genotypes of Thai citizens by 2027, anchored under the Ministry of Higher Education, Science, Research and Innovation and operationally coordinated by NSTDA. As of 2026, cohort recruitment has cleared the 18,000 WGS milestone with a planned acceleration through 2027. The resulting dataset gives ethnic-Thai-calibrated training data unavailable in Western reference cohorts (1000 Genomes, gnomAD, All of Us) and positions Thai labs as the structural exclusive supplier for ASEAN AI compound discovery work. Commercial-access tier is expected to activate by 2027 once cohort passes 25,000 WGS milestone.
Figure in context
The Genome Thailand programme targets 50,000 whole-genome sequences plus 200,000 array genotypes of Thai citizens by 2027, anchored under the Ministry of Higher Education, Science, Research and Innovation and operationally coordinated by NSTDA. As of 2026, cohort recruitment has cleared the 18,000 WGS milestone with a planned acceleration through 2027. The resulting dataset gives ethnic-Thai-calibrated training data unavailable in Western reference cohorts (1000 Genomes, gnomAD, All of Us) and positions Thai labs as the structural exclusive supplier for ASEAN AI compound discovery work. Commercial-access tier is expected to activate by 2027 once cohort passes 25,000 WGS milestone.
Interpretation notes
What this tells you
The Genome Thailand programme targets 50,000 whole-genome sequences plus 200,000 array genotypes of Thai citizens by 2027, anchored under the Ministry of Higher Education, Science, Research and Innovation and operationally coordinated by NSTDA. As of 2026, cohort recruitment has cleared the 18,000 WGS milestone with a planned acceleration through 2027. The resulting dataset gives ethnic-Thai-calibrated training data unavailable in Western reference cohorts (1000 Genomes, gnomAD, All of Us) and positions Thai labs as the structural exclusive supplier for ASEAN AI compound discovery work. Commercial-access tier is expected to activate by 2027 once cohort passes 25,000 WGS milestone.
What not to do with it
Values in thousands of completed whole-genome sequences. Array genotype cohort (200K target) sits separately. 2027 target represents the programme roadmap; commercial-access tier activation expected once 25K WGS milestone is cleared.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Thailand AI drug discovery cost-per-validated-target (2026)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.